See more : Lion One Metals Limited (LLO.AX) Income Statement Analysis – Financial Results
Complete financial analysis of BriaCell Therapeutics Corp. (BCTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BriaCell Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ero Copper Corp. (ERO.TO) Income Statement Analysis – Financial Results
- CMS Info Systems Limited (CMSINFO.BO) Income Statement Analysis – Financial Results
- Qingdao Port International Co., Ltd. (601298.SS) Income Statement Analysis – Financial Results
- Globeride, Inc. (7990.T) Income Statement Analysis – Financial Results
- Indian Energy Exchange Limited (IEX.NS) Income Statement Analysis – Financial Results
BriaCell Therapeutics Corp. (BCTX)
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 82.58K | 15.53K | 15.14K | 15.57K | 13.99K | 14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -82.58K | -15.53K | -15.14K | -15.57K | -13.99K | -14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.75M | 15.34M | 8.02M | 1.32M | 2.22M | 3.74M | 2.39M | 1.71M | 723.43K | 105.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -178.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.97M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 114.12K | 129.06K | 8.58K |
| Other Expenses | 0.00 | 0.00 | -15.29M | -1.33M | -2.24M | -3.75M | -312.92K | 290.00 | 1.79K | 565.00 | 1.21K | 404.00 | -4.23K | 2.40K | 1.33K | 2.33K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 32.73M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Cost & Expenses | 32.81M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Interest Income | 0.00 | 891.21K | 136.73K | 3.15K | 39.48 | 9.13K | 12.27K | 5.16K | 3.63K | 7.09K | 12.00K | 16.90K | 38.01K | 13.36K | 2.90K | 2.73K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 979.00 | 46.10K | 27.00K | 23.82K | 15.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 82.58K | 15.27K | 15.27K | 15.26K | 15.26K | 14.25K | 12.97K | 232.68 | 907.21 | 434.31 | 1.11K | 392.08 | 1.72K | 2.51K | 1.29K | 154.20 | 12.72K | 5.10K | -1.13K |
| EBITDA | -4.77M | -30.67M | -15.13M | -8.69M | -3.97M | -6.67M | -4.96M | -3.22M | -2.18M | -1.80M | -2.61K | -462.53K | -68.23K | -1.01M | 255.79K | -233.72K | -114.12K | -129.06K | -8.58K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.81M | -23.27M | -15.29M | 3.69M | 1.38M | 946.42K | -3.82M | -2.58M | -1.67M | -1.44M | -437.27K | -424.26K | -1.20M | -1.05M | -324.57K | -233.87K | -114.12K | -129.06K | -8.58K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 28.02M | 2.97M | 3.74M | -6.84M | -85.10K | 0.00 | -1.59M | 634.11K | 481.60K | -1.24M | -7.71M | 55.56K | 202.71K | -37.17K | -595.34K | 2.51K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.79M | -20.30M | -11.55M | 3.69M | 1.38M | 946.42K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.09M | -919.91K | -231.36K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 62.85K | -152.62K | 30.73K | 6.58M | -72.25K | 343.74K | 1.59M | 638.59K | 547.97K | 2.05M | 8.45M | -44.35K | -200.92K | -24.03K | 601.48K | 12.46K | -12.72K | -5.10K | 1.13K |
| Net Income | -4.79M | -20.30M | -11.58M | -2.89M | 1.38M | 602.68K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.08M | -900.74K | -228.81K | -98.93K | -116.41K | -8.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.61 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EPS Diluted | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.32 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| Weighted Avg Shares Out | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.81K | 339.71K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
| Weighted Avg Shares Out (Dil) | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.82K | 352.98K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report unprecedented activity...
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the...
October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, recognizes that October is Breast Cancer Awareness...
BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that...
BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will...
BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce...
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that its registration-enabling...
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of...
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders
TORONTO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that the Company has closed the previously...
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted...
Source: https://incomestatements.info
Category: Stock Reports